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Summary Etoposide is being used increasingly in the treatment of a variety of malignant conditions and in
conjunction with autologous bone marrow transplantation. We have examined the effect of the drug on
human CFU-GM as an indication of the response of these bone marrow progenitor cells to measured plasma
concentrations. When etoposide is present in the routine assay for 7 days, 50% growth of colony-forming
CFU-GM occurs at a concentration of 0.0098ygml-1. When bovine serum albumin or human serum
albumin is present this value is increased to 0.042 and 0.375yigml-
. Protein binding therefore plays an
important part in modifying in vitro response and possibly in vivo response of these progenitor cells to
etoposide.
Etoposide (4-6-demethylepipodophyllotoxin-9-(4-6-
0-ethylidene-B-D-glucopyranoside) is being used
increasingly in the treatment of malignancy (Cavilli
et al., 1978., Radice et al., 1979., Newlands &
Bagahawe, 1980) and is also toxic towards some
experimental tumours (D'Incali et al., 1981) and
cell lines (Huang et al., 1973; Rivera et al., 1975;
Loike & Horwitz, 1976; Cavilli et al., 1978).
Etoposide is a derivative of naturally occuring
podophyllotoxin and exerts its cytotoxic effect by
several mechanisms including inhibition of the S
and G2 phases of the cell cycle (Grieder et al.,
1974; Misra & Roberts, 1975; Krishan et al., 1980).
Etoposide produces single and double-strand breaks
in the DNA molecules as well as damaging nucleic
acid-protein cross-links (Wozniak & Ross, 1983). In
common with related drugs it also inhibits the
uptake of nucleotides into the cell possibly by the
inhibition of macromolecular synthesis. (Grieder et
al., 1974; Wozniak and Ross, 1983). Recent studies
(Yalowich & Goldman, 1984) suggest that
etoposide inhibits both the uptake of nucleotides
into the cell and subsequent incorporation into
DNA. This property is not shared by podo-
phyllotoxin.
More recently etoposide has been used in high
doses with autologous bone marrow transplantation
(Wolff et al., 1983; Littlewood et al., 1985). In these
circumstances it is clearly important that reinfusion
is delayed until plasma concentrations are below
levels which are toxic towards the stem cell
population. Pharmacokinetic studies using radio-
actively labelled etoposide indicate that the
clearance half-life is from 5.7 to 11.5h. (Allen &
Creaven, 1975; D'Incali et al., 1981; Evans et al.,
1982). Recent studies using HPLC (Littlewood et
al., 1985) suggest a slower clearance and that an
appreciable period is required for complete
clearance of the drug. To date there are no data
relating plasma concentrations to bone marrow
toxicity. We examined the effects of etoposide on
the human CFU-GM population in vitro in order
to obtain an indication of the sensitivity of the
bone marrow to the concentrations of the drug that
have been measured in plasma. Etoposide is known
to bind strongly to albumin (Allen & Creaven,
1975) and we have therefore examined the effect of
various serum albumin preparations on the
response of CFU-GM to the agent.
Materials and methods
Bone marrow was obtained from ribs resected from
patients undergoing thoracotomy who were
haematologically normal. In all cases CFU-GM
growth was within normal limits.
Incubation with etoposide
Solutions of Etoposide (Bristol Myers UK Ltd)
were prepared immediately before use in methanol
(Analar grade, BDH Ltd, UK) and diluted ap-
propriately with alpha medium. Preliminary
experiments were carried out to ensure that the
concentrations of alcohol used had no effect on the
assay. Bone marrow mononuclear cells were
prepared and assayed as previously described
(Bailey-Wood et al., 1984) at a concentration of
200,000ml-1. Incubation was for 7days in alpha
medium containing human placenta conditioned
medium and 0.3% agar in 5% CO2 in a fully
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humidified incubator. Colonies were defined as
aggregates of >40 cells and clusters as aggregates
of between 4 and 40 cells. Etoposide was added to
the incubation system at concentrations detailed in
the text and therefore incubated with the cells for
7days.
Human serum albumin (HSA) (Fraction V
Sigma) and bovine serum albumin (BSA) (Armour
Pharmaceutical Company) solutions were prepared
in water. The pH was adjusted to 7.4 and the
osmolality to 280mosmolkg-1 using the Osmomat
030 osmometer (Gonotext), before sterilisation by
filtration through a 0.22,um Millipore filter.
All assays were performed in duplicate and are
the results of from 4 to 5 experiments. Sensitivity to
etoposide was quantitated in terms of the
concentration giving 50% survival of the cells
(D50). This concentration was the mean value
derived from all the experiments. Results are
expressed as the mean value +s.e. and significance
tested using Students t-test.
Results
The mean number of CFU-GM in the bone
marrow preparations used in this study was
198+124 (s.d.) (range 84-428) per 200,000 mono-
nuclear cells plated. This figure is within the range
of values obtained in this laboratory for similar
bone marrow preparations from a large number of
normal subjects. Colonies obtained after 7days
incubation are mainly granulocytic (>80%) the
remainder are largely mixed granulocytic-monocytic
with a small number ofwholly monocytic colonies.
Figure 1 shows the effect of etoposide on CFU-
GM growth. There was a simple log-linear
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Figure 1 Effects of etoposide on colony-forming (0)
and cluster-forming (0) CFU-GM. Incubation was
for 7days in the soft agar assay system with human
placenta conditioned medium as a source of colony
stimulating factor.
relationship between drug concentration and CFU-
GM with a 50% survival (D50) at a mean drug
concentration of 0.0098+0.0017yugml-1. Cluster-
forming CFU-GM were less sensitive to the drug
with a D50 value of 0.075+0.02pgml-1.
The effect of BSA on the cytotoxicity of etopo-
side towards CFU-GM is illustrated in Figure 2.
Etoposide was present at a concentration of 0.018
and 0.036pgml-1 and BSA at increasing concen-
trations up to 40mgml-1. Results are expressed as
a percentage of the control value for cultures also
containing BSA. In the absence of BSA the
percentage of CFU-GM present in the cultures
containing 0.018pgml-1 of etoposide was 28 and
5% in the presence of 0.036pgml-' etoposide.
There was a marked increase in colony number
with increasing BSA up to a plateau concentration
of - 20mgml-1. This increase was - 10 fold at the
higher drug concentration and - 2 fold at the lower
concentration. Subsequent experiments using serum
albumin preparations have been performed at a
concentration of 25mgml-1, this being sufficiently
high to afford maximum protection over the range
of etoposide used in these studies without incuring
the practical difficulties of preparing accurate
solutions of albumin at high concentration.
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Figure 2 Effect of BSA on the response of CFU-GM
to etoposide at a concentration of 0.018ugmlml (0)
and 0.036jugml -I (0). Results are expressed as a
percentage of the control containing BSA but not
etoposide.
When incorporated into the assay system at this
concentration (Figure 3) marked protection of the
CFU-GM population was observed. Very little
inhibition of CFU-GM growth was found at
concentrations below 0.01 pgml-1, probablyEFFECT OF ETOPOSIDE ON HUMAN CFU-GM 615
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Figure 3 Effect of etoposide on colony-forming (0)
and cluster-forming (0) CFU-GM (mean+s.e.) in the
presence of BSA at a concentration of 25 mgml.
reflecting almost complete binding of etoposide
to BSA. Above this concentration the effect of the
drug was more pronounced than in the absence of
albumin. This was indicated by the steeper slope of
the dose response graph and is probably due to the
increasing saturation of the BSA. The D50
concentration in the presence of BSA was
0.043+0.011 pgml-1. This was significantly higher
than in the absence of BSA (P<0.01). The response
of the cluster-forming CFU-GM population was of
a similar pattern; the D50 value was
0.l +0.020pgml-1.
The effect of HSA was greater than that of BSA
(Figure 4). Very little inhibition of CFU-GM
growth was observed below an etoposide concen-
tration of 0. pgml-1. Above this value inhibition
was apparent with a D50 concentration of
0.375+0.17 pgml-'. This was significantly higher
than in the presence of BSA (P<0.001) or in the
absence of added serum albumin. Again cluster-
forming CFU-GM were rather less sensitive to the
drug. The D50 concentration was
0.71 +0.04pgml-1 which was significantly higher
than in the absence or presence of BSA (P<0.001
in each case).
Table I summarises the relative effects of BSA
and HSA on the response of CFU-GM to
etoposide.
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Figure 4 Effect of etoposide on colony-forming (0)
and cluster-forming (0) CFU-GM (mean+s.e.) in the
presence of HSA at a concentration of 25mgml -.
Discussion
Etoposide has been used in the treatment of a wide
range of malignancies. In common with most other
cytotoxic agents the dose-limiting factor in its use is
myelosuppression with both a leucopenia and
thrombocytopenia occuring about 7days after
administration. There are no published data
describing the in vitro effects of etoposide on the
bone marrow. The CFU-GM population represents
only a part of the myelopoietic system and clearly
does not measure true stem cell response. The
myeloid system does seem particularly sensitive to
the drug and the CFU-GM assay is therefore
probably the most relevant. We have examined the
effect of etoposide on both the colony forming and
cluster-forming population as being representative
of early and late progenitor populations.
Because of the nature of the assay incubation
with drugs can only be carried out for relatively
short periods prior to plating the cells in agar or
alternatively during the full 7day period of
incubation. The latter was chosen for this study for
several reasons. Firstly, clinical protocols usually
employ several courses of etoposide over a period
of a number of days. Secondly, because of the
relatively slow rate of clearance of etoposide even
at 96h post infusion concentrations of 0.1 pgml-1
Table I D50 conc. (pgml-1) in presence and absence of serum
albumin
D50 conc.
CFU-GM No albumin +BSA +HSA
Colonies 0.0098+0.0017 0.042+0.019 0.375+0.170
Clusters 0.075+0.020 0.11+0.03 0.71+0.01
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could be detected in the plasma (Littlewood et al.,
1985).
Current evidence suggests that etoposide is
largely effective during the S and G2 phases of the
cell cycle though the mode of action may be
complex (Stahelin, 1970; Drewinko and Barlogie,
1976; Krishan et al., 1983). The response of the
CFU-GM population towards etoposide showed a
simple relationship as might be expected
considering that colony formation takes place by
virtue of cell division induced by the action of
CSA. The lower sensitivity of the cluster-forming
CFU (Table I) reflects the lower level of
proliferative capacity of these progenitors.
The effect of serum albumin on the sensitivity of
the CFU-GM to etoposide is both interesting and
important. The binding of cytotoxic drugs to
protein influences their in vivo action but there has
not been any previous attempt to evaluate this
effect in vitro using an assay for myeloid progenitor
cells. Etoposide is strongly bound to human serum
albumin with -94% of the drug being bound at
typical plasma concentrations (Allen & Craven,
1975). For reasons described in the text serum
albumin preparations were present in the assay at a
concentration of 25mgml -1. The contribution
made by calf serum amounted to - 6mgml -1.
These combined values are slightly less than normal
serum albumin concentration of 34-45mgml-1.
Increasing the albumin concentration further did
not affect the response of the progenitor cells to
etoposide over the range of drug concentration
employed in these experiments. In the absence of
added serum albumin the CFU-GM population is
sensitive to very low concentrations of etoposide
when presumably most of the drug is present in the
free form. In the presence of added BSA a ten-fold
higher concentration of drug is necessary to elicit a
reduction of CFU-GM number although because of
the greater slope of the dose response curve the
D50 concentration was increased only some 4.5
fold. The effect of HSA was even more marked
resulting in a decrease of only 15% at an
etoposide concentration of 0.15 jgml 1.
The binding of etoposide to albumin therefore
plays a significant role in the interpretation of the
pharmacokinetic data available on etoposide. The
increase in D50 concentration with HSA agrees well
with the protein binding data suggesting 6% free
drug in the plasma. The greater efficacy of HSA
compared to BSA agrees with equilibrium dialysis
data showing a greater affinity of HSA for
etoposide (Littlewood, unpublished data).
These data provide a much clearer picture of the
relationship between plasma concentrations of
etoposide and the effect on the granulomonocytic
progenitor cells. The data can be used as a guide to
the plasma levels of drugs which are necessary to
achieve a cytotoxic effect on the marrow and
secondly as a guide to the maximum plasma levels
that can be tolerated prior to reinfusion of bone
marrow during autologous bone marrow
transplantation.
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